{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}],"title":"No acute GVHD"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Grade I acute GVHD"},{"measurements":[{"groupId":"OG000","value":"25"}],"title":"Grade II acute GVHD"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Grade III acute GVHD"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Grade IV acute GVHD"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Steroid refractory acute GVHD"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Number of participants with aGVHD and severity of aGVHD within the first 360 days post-transplant as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Acute GVHD is graded by standard criteria, and all suspected cases of acute GVHD will be confirmed histologically by biopsy of an affected organ. The severity of acute GVHD is determined by an assessment of the degree of involvement of the skin, liver, and gastrointestinal tract. Grade I is characterized as mild disease, Grade II as moderate, Grade III as severe (involvement of any organ system), and Grade IV as life-threatening.","groups":[{"description":"CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC and tacrolimus for GVHD prophylaxis","id":"OG000","title":"Overall Study Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within 360 days of transplant","title":"Number of Participants With Acute Graft-vs-host Disease (GVHD): Grade I-IV, Including Those With no Reportable Acute GVHD","type":"PRIMARY","unitOfMeasure":"Participants"}